Prevalence, Risk Factors and Course of Osteoporosis in Patients with Crohn's Disease at a Tertiary Referral Center.
Crohn’s disease
bisphosphonates
bone mineral density
inflammatory bowel disease
osteopenia
osteoporosis
steroids
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
10 Dec 2019
10 Dec 2019
Historique:
received:
18
11
2019
revised:
05
12
2019
accepted:
10
12
2019
entrez:
15
12
2019
pubmed:
15
12
2019
medline:
15
12
2019
Statut:
epublish
Résumé
Patients with Crohn's disease are at increased risk for fractures due to low bone mineral density (BMD). Real-world data are necessary to optimize surveillance and treatment strategies. Patients with Crohn's disease who underwent at least one dual-energy X-ray absorptiometry (DXA) scans were recruited. The primary study endpoints were (1) prevalence of osteoporosis, and (2) factors influencing changes of BMD. To identify potential risk factors for reduced BMD, Mann-Whitney U-test was used for ordinal and continuous variables and 39.9% of the patients were diagnosed with normal BMD, 40.2% with osteopenia, and 19.8% with osteoporosis. The main risk factors for osteoporosis were low body mass index (BMI), previous bowel resections and male sex. The main risk factors for reduced BMD during further along the disease course were steroid use, history of immunomodulator treatment, female sex and decreased BMI. Low BMI, previous bowel resections and male sex were the main risk factors for the development of osteoporosis. Steroid use reduced BMD even under anti-inflammatory therapy, underlining that they should be used with great care in that patient group.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with Crohn's disease are at increased risk for fractures due to low bone mineral density (BMD). Real-world data are necessary to optimize surveillance and treatment strategies.
METHODS
METHODS
Patients with Crohn's disease who underwent at least one dual-energy X-ray absorptiometry (DXA) scans were recruited. The primary study endpoints were (1) prevalence of osteoporosis, and (2) factors influencing changes of BMD. To identify potential risk factors for reduced BMD, Mann-Whitney U-test was used for ordinal and continuous variables and
RESULTS
RESULTS
39.9% of the patients were diagnosed with normal BMD, 40.2% with osteopenia, and 19.8% with osteoporosis. The main risk factors for osteoporosis were low body mass index (BMI), previous bowel resections and male sex. The main risk factors for reduced BMD during further along the disease course were steroid use, history of immunomodulator treatment, female sex and decreased BMI.
CONCLUSION
CONCLUSIONS
Low BMI, previous bowel resections and male sex were the main risk factors for the development of osteoporosis. Steroid use reduced BMD even under anti-inflammatory therapy, underlining that they should be used with great care in that patient group.
Identifiants
pubmed: 31835600
pii: jcm8122178
doi: 10.3390/jcm8122178
pmc: PMC6947604
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Osteoporos Int. 2002 Oct;13(10):777-87
pubmed: 12378366
BMB Rep. 2010 Aug;43(8):524-9
pubmed: 20797313
Pol Arch Intern Med. 2018 Aug 31;128(7-8):447-454
pubmed: 30057387
J Bone Miner Metab. 2014 Jul;32(4):378-92
pubmed: 24122251
Lancet. 1993 Jan 9;341(8837):72-5
pubmed: 8093403
Dig Dis Sci. 2001 Nov;46(11):2521-8
pubmed: 11713964
Dig Dis. 2019;37(4):284-290
pubmed: 30799399
Arch Osteoporos. 2018 Mar 3;13(1):16
pubmed: 29502242
Am J Med. 2009 Jul;122(7):599-604
pubmed: 19559158
Gut. 2006 Jun;55(6):749-53
pubmed: 16698746
Int J Colorectal Dis. 2006 Dec;21(8):758-66
pubmed: 16463035
Gut. 1987 Apr;28(4):410-5
pubmed: 3583068
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Dig Dis Sci. 2014 Aug;59(8):1878-84
pubmed: 24619280
Arch Osteoporos. 2014;9:182
pubmed: 24847682
Dig Dis Sci. 1992 Sep;37(9):1396-403
pubmed: 1505291
Clin Gastroenterol Hepatol. 2007 Jun;5(6):721-8
pubmed: 17482522
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
Ann Med. 2010 Mar;42(2):97-114
pubmed: 20166813
JAMA. 2019 Aug 27;322(8):736-745
pubmed: 31454046
Osteoporos Int. 2018 Nov;29(11):2389-2397
pubmed: 29909470
Therap Adv Gastroenterol. 2019 Jul 31;12:1756284819862152
pubmed: 31391867
BMJ. 1996 May 18;312(7041):1254-9
pubmed: 8634613
Clin Gastroenterol Hepatol. 2014 Jan;12(1):32-44.e5
pubmed: 23981521
Scand J Gastroenterol. 1996 Apr;31(4):367-71
pubmed: 8726305
Osteoporos Int. 1994 Nov;4(6):368-81
pubmed: 7696835
J Clin Gastroenterol. 2019 Jul;53(6):441-448
pubmed: 29672437
J Crohns Colitis. 2014 Dec;8(12):1693-701
pubmed: 25175812
Gastroenterology. 1994 Oct;107(4):1031-9
pubmed: 7926456
Endocr Rev. 2002 Aug;23(4):508-16
pubmed: 12202465
Clin Nutr. 2001 Dec;20(6):541-6
pubmed: 11884003
Gut. 1997 Feb;40(2):228-33
pubmed: 9071937
Gastroenterol Hepatol (N Y). 2011 Apr;7(4):235-41
pubmed: 21857821
Am J Gastroenterol. 2008 Jun;103(6):1451-9
pubmed: 18422819